摘要
目的探讨六西格玛管理法在临床生化不合格标本中的应用效果。方法选取2019年1月—2020年12月贵航贵阳医院检验科生化室不合格标本为管理前,实施六西格玛管理模式后2021年1月—2022年12月的不合格标本为管理后,对管理前后不合格标本进行分析。结果2019年1月—2022年12月生化实验室标本不合格率为0.61‰,其中2019年1月—2020年12月的标本不合格率为0.98‰,实施六西格玛管理模式后2021年1月—2022年12月的不合格率为0.26‰,差异有统计学意义(P<0.01)。不合格标本以儿科(14.98%)、心血管内科(9.39%)、呼吸与危重症医学科(8.48%)和内分泌科(8.12%)最为常见。标本溶血(24.01%)、抗凝标本凝集(20.76%)和标签不合格(20.22%)是生化实验室标本不合格的最主要原因。结论应用六西格玛管理法可有效减少临床生化检测中不合格标本发生率,有助于提高临床实验室生化检验的质量水平。
Objective To investigate the effect of six Sigma management in clinical biochemical specimens.Methods The unqualified specimens in the biochemical laboratory of Guihang Guiyang Hospita from January 2019 to December 2020 were selected as before management,and the unqualified specimens from January 2021 to December 2022 after the implementation of six Sigma management mode were selected as after management.The unqualified specimens were analyzed before and after management.Results The unqualified rate of biochemical laboratory specimens from January 2019 to December 2022 was 0.61‰,and the unqualified rate from January 2019 to December 2020 specimens was 0.98‰,and the unqualified rate from January 2021 to December 2022 was 0.26‰,the difference was statistically significant(P<0.01).The unqualified specimens were most common in pediatrics(14.98%),cardiovascular medicine(9.39%),respiratory and critical care medicine(8.48%)and endocrinology(8.12%).Hemolysis(24.01%),agglutination(20.76%)and unqualified labeling(20.22%)were the most important reasons of unqualified biochemical laboratory specimens.Conclusion The application of six Sigma management method can effectively reduce the incidence of unqualified specimens in clinical biochemical testing,and help to improve the quality level of clinical laboratory biochemical testingy.
作者
胡鑫
刘阳
熊仕琳
HU Xin;LIU Yang;XIONG Shilin(Department of Clinical Laboratory,Guihang Guiyang Hospital,Guiyang Guizhou 550009,China)
出处
《中国卫生标准管理》
2024年第6期94-97,共4页
China Health Standard Management
